| 28% of premenopausal females treated at 0.25 mg Betaseron ® reported
menstrual disorders.
All of these reports were of mild to moderate severity and included:
intermenstrual bleeding and spotting, early or delayed menses, decreased
days of menstrual flow, and clotting and spotting during menstruation.
|
